Central Nervous System (CNS) Therapeutics Market By Disease Type (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033
The Central Nervous System (CNS) Therapeutics Market was valued for $114,145.58 million in 2023 and is estimated to reach $199,098.30 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033. The central nervous system (CNS) is a complex network of nerves and cells that play a crucial role in coordinating and regulating the body's activities. It comprises the brain and spinal cord, serving as the primary control center for the entire nervous system. Central nervous system therapeutics aim to alleviate symptoms, improve cognitive function, and slow down disease progression. Central nervous system therapeutics primarily involve the use of drugs to address disorders and imbalances within the central nervous system. The medications target various neurological and psychiatric conditions, ranging from neurodegenerative diseases like Alzheimer's and Parkinson's to mental health disorders such as mood disorders, anxiety, and psychotic disorders.
The central nervous system (CNS) therapeutics market is expected to register significant growth, owing to surge in prevalence of CNS disorders, and favorable government initiative such as research grants to support research and innovation. The rise in prevalence of CNS disorders has emerged as a major driver for the central nervous system (CNS) therapeutics market. This can be attributed to the stressful lifestyle, negligence towards mental health, and rise in geriatric population. The aging population, in particular, has witnessed a surge in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. For instance, according to Center for Disease Control and Prevention, it was estimated that around 6.7 million Americans aged 65 years or older had Alzheimer's disease.
Additionally, the modern, fast-paced lifestyle, marked by high stress levels and sedentary habits, has been associated with a heightened risk of mental health disorders like anxiety and depression. For instance, according to National Library of Medicine, in 2021, it was estimated that that more than one in five U.S. adults live with a mental illness. Pharmaceutical companies are increasingly focusing on the discovery and development of novel drugs and therapies targeting various CNS conditions. Breakthroughs in neuroscience and a deeper understanding of the underlying mechanisms of these disorders have paved the way for more effective and targeted treatment options. The demand for CNS therapeutics is expected to surge as patients and healthcare providers seek advanced interventions that not only alleviate symptoms but also address the root causes of the CNS disorders. Thus, the rise in prevalence of CNS disorders is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market.
In addition, favorable government initiatives such as research grants to support research and innovation in treating central nervous system disorders are expected to drive the growth of the market. Governments around the world are recognizing the critical need to address conditions such as neurodegenerative diseases, psychiatric disorders, and neurological disorders, which collectively pose a substantial burden on global healthcare systems. One notable initiative driving the research is the provision of research grants specifically dedicated to advancing our understanding of the central nervous system and developing novel therapeutic interventions. The research grants serve as a catalyst for scientific exploration, fostering collaboration between researchers, academia, and pharmaceutical companies. For instance, American Parkinson Disease Association, awards research grant of maximum of $75,000 to research scientists. American Parkinson Disease Association Research Grants are intended to support research aimed at developing new insights into the pathophysiology, etiology and treatment of Parkinson’s disease.
Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. American Parkinson Disease Association seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation. By providing grants governments agencies are playing a pivotal role in accelerating the development of innovative treatments and therapies. Thus, favorable government initiatives such as research grants are expected to drive the growth of the market.
However, the high cost of the central nervous system (CNS) therapeutic drug has emerged as major concerns restraining the growth of the market. The complex nature of neurological disorders often necessitates sophisticated and specialized therapeutic interventions, leading to elevated research and development expenses. Additionally, the stringent regulatory requirements imposed by health authorities contribute to the lengthy and resource-intensive process of bringing CNS drugs to market. These substantial costs are then transferred to end-users, comprising patients and healthcare systems, thereby limiting accessibility and affordability of the CNS drugs. Thus, the high cost of the central nervous system (CNS) therapeutic drug might restrain the growth of the market.
The central nervous system (CNS) therapeutics market is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, cancer, and others. The mental health segment is further segmented into mental health anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others.
In addition, the neurodegenerative diseases are further classified into Alzheimer's disease, Parkinson’s disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Biogen Inc, Johnson and Johnson, Eli Lilly and Company Inc, Merck and Co. Inc, F. Hoffmann-La Roche AG, Novartis AG, Takeda Pharmaceuticals, Viatris, UCB, and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central nervous system (cns) therapeutics market analysis from 2023 to 2033 to identify the prevailing central nervous system (cns) therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the central nervous system (cns) therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global central nervous system (cns) therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
Neurodegenerative Diseases
Disease Type
Alzheimer's Disease
Parkinson’s Disease
Multiple Sclerosis
Huntington's Disease
Amyotrophic Lateral Sclerosis
Others
Infectious Diseases
CNS Cancer
Others
Neurovascular Diseases
CNS Trauma
Mental Health
Disease Type
Anxiety Disorders
Epilepsy
Mood Disorders
Psychotic Disorders
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Johnson and Johnson
Eli Lilly and Company.
Merck & Co Inc
Novartis AG
Biogen
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche AG
Takeda Pharmaceutical Company Ltd.
Viatris Inc.
UCB Pharma
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. High intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of the neurological conditions
- 3.4.1.2. Rise in awareness and diagnosis of CNS disorders
- 3.4.1.3. Surge in research and development by key players
- 3.4.2. Restraints
- 3.4.2.1. High cost of central nervous system (CNS) therapeutics
- 3.4.3. Opportunities
- 3.4.3.1. Technological advancements in drug delivery
- CHAPTER 4: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Neurovascular Diseases
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. CNS Trauma
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Mental Health
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.4.4. Mental Health Central Nervous System (CNS) Therapeutics Market by Disease Type
- 4.5. Neurodegenerative Diseases
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.5.4. Neurodegenerative Diseases Central Nervous System (CNS) Therapeutics Market by Disease Type
- 4.6. Infectious Diseases
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- 4.7. CNS Cancer
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
- 4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country
- CHAPTER 5: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION
- 5.1. Overview
- 5.1.1. Market size and forecast By Region
- 5.2. North America
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by Disease Type
- 5.2.3. Market size and forecast, by country
- 5.2.3.1. U.S.
- 5.2.3.1.1. Market size and forecast, by Disease Type
- 5.2.3.2. Canada
- 5.2.3.2.1. Market size and forecast, by Disease Type
- 5.2.3.3. Mexico
- 5.2.3.3.1. Market size and forecast, by Disease Type
- 5.3. Europe
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by Disease Type
- 5.3.3. Market size and forecast, by country
- 5.3.3.1. Germany
- 5.3.3.1.1. Market size and forecast, by Disease Type
- 5.3.3.2. France
- 5.3.3.2.1. Market size and forecast, by Disease Type
- 5.3.3.3. UK
- 5.3.3.3.1. Market size and forecast, by Disease Type
- 5.3.3.4. Italy
- 5.3.3.4.1. Market size and forecast, by Disease Type
- 5.3.3.5. Spain
- 5.3.3.5.1. Market size and forecast, by Disease Type
- 5.3.3.6. Rest of Europe
- 5.3.3.6.1. Market size and forecast, by Disease Type
- 5.4. Asia-Pacific
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by Disease Type
- 5.4.3. Market size and forecast, by country
- 5.4.3.1. Japan
- 5.4.3.1.1. Market size and forecast, by Disease Type
- 5.4.3.2. China
- 5.4.3.2.1. Market size and forecast, by Disease Type
- 5.4.3.3. India
- 5.4.3.3.1. Market size and forecast, by Disease Type
- 5.4.3.4. Australia
- 5.4.3.4.1. Market size and forecast, by Disease Type
- 5.4.3.5. South Korea
- 5.4.3.5.1. Market size and forecast, by Disease Type
- 5.4.3.6. Rest of Asia-Pacific
- 5.4.3.6.1. Market size and forecast, by Disease Type
- 5.5. LAMEA
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by Disease Type
- 5.5.3. Market size and forecast, by country
- 5.5.3.1. Brazil
- 5.5.3.1.1. Market size and forecast, by Disease Type
- 5.5.3.2. Saudi Arabia
- 5.5.3.2.1. Market size and forecast, by Disease Type
- 5.5.3.3. South Africa
- 5.5.3.3.1. Market size and forecast, by Disease Type
- 5.5.3.4. Rest of LAMEA
- 5.5.3.4.1. Market size and forecast, by Disease Type
- CHAPTER 6: COMPETITIVE LANDSCAPE
- 6.1. Introduction
- 6.2. Top winning strategies
- 6.3. Product mapping of top 10 player
- 6.4. Competitive dashboard
- 6.5. Competitive heatmap
- 6.6. Top player positioning, 2023
- CHAPTER 7: COMPANY PROFILES
- 7.1. Johnson and Johnson
- 7.1.1. Company overview
- 7.1.2. Key executives
- 7.1.3. Company snapshot
- 7.1.4. Operating business segments
- 7.1.5. Product portfolio
- 7.1.6. Business performance
- 7.2. Eli Lilly and Company.
- 7.2.1. Company overview
- 7.2.2. Key executives
- 7.2.3. Company snapshot
- 7.2.4. Operating business segments
- 7.2.5. Product portfolio
- 7.2.6. Business performance
- 7.2.7. Key strategic moves and developments
- 7.3. Merck & Co Inc
- 7.3.1. Company overview
- 7.3.2. Key executives
- 7.3.3. Company snapshot
- 7.3.4. Operating business segments
- 7.3.5. Product portfolio
- 7.3.6. Business performance
- 7.4. Novartis AG
- 7.4.1. Company overview
- 7.4.2. Key executives
- 7.4.3. Company snapshot
- 7.4.4. Operating business segments
- 7.4.5. Product portfolio
- 7.4.6. Business performance
- 7.4.7. Key strategic moves and developments
- 7.5. Teva Pharmaceutical Industries Ltd.
- 7.5.1. Company overview
- 7.5.2. Key executives
- 7.5.3. Company snapshot
- 7.5.4. Operating business segments
- 7.5.5. Product portfolio
- 7.5.6. Business performance
- 7.5.7. Key strategic moves and developments
- 7.6. F. Hoffmann-La Roche AG
- 7.6.1. Company overview
- 7.6.2. Key executives
- 7.6.3. Company snapshot
- 7.6.4. Operating business segments
- 7.6.5. Product portfolio
- 7.6.6. Business performance
- 7.7. Takeda Pharmaceutical Company Ltd.
- 7.7.1. Company overview
- 7.7.2. Key executives
- 7.7.3. Company snapshot
- 7.7.4. Operating business segments
- 7.7.5. Product portfolio
- 7.7.6. Business performance
- 7.8. Viatris Inc.
- 7.8.1. Company overview
- 7.8.2. Key executives
- 7.8.3. Company snapshot
- 7.8.4. Operating business segments
- 7.8.5. Product portfolio
- 7.8.6. Business performance
- 7.9. UCB Pharma
- 7.9.1. Company overview
- 7.9.2. Key executives
- 7.9.3. Company snapshot
- 7.9.4. Operating business segments
- 7.9.5. Product portfolio
- 7.9.6. Business performance
- 7.10. Biogen
- 7.10.1. Company overview
- 7.10.2. Key executives
- 7.10.3. Company snapshot
- 7.10.4. Operating business segments
- 7.10.5. Product portfolio
- 7.10.6. Business performance
- 7.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 02. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY REGION, 2023-2033 ($MILLION)
- TABLE 03. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY REGION, 2023-2033 ($MILLION)
- TABLE 04. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY REGION, 2023-2033 ($MILLION)
- TABLE 05. GLOBAL MENTAL HEALTH CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 06. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2033 ($MILLION)
- TABLE 07. GLOBAL NEURODEGENERATIVE DISEASES CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 08. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2033 ($MILLION)
- TABLE 09. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY REGION, 2023-2033 ($MILLION)
- TABLE 10. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
- TABLE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION, 2023-2033 ($MILLION)
- TABLE 12. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 13. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 14. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 15. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 16. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 17. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 18. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 19. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 20. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 21. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 22. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 23. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 24. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 25. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 27. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 28. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 29. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 30. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 31. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 32. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 33. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 34. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
- TABLE 39. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 40. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 41. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
- TABLE 42. JOHNSON AND JOHNSON: SERVICE SEGMENTS
- TABLE 43. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 44. ELI LILLY AND COMPANY.: KEY EXECUTIVES
- TABLE 45. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
- TABLE 46. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
- TABLE 47. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
- TABLE 48. ELI LILLY AND COMPANY.: KEY STRATERGIES
- TABLE 49. MERCK & CO INC: KEY EXECUTIVES
- TABLE 50. MERCK & CO INC: COMPANY SNAPSHOT
- TABLE 51. MERCK & CO INC: PRODUCT SEGMENTS
- TABLE 52. MERCK & CO INC: PRODUCT PORTFOLIO
- TABLE 53. NOVARTIS AG: KEY EXECUTIVES
- TABLE 54. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 55. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 56. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 57. NOVARTIS AG: KEY STRATERGIES
- TABLE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
- TABLE 64. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
- TABLE 65. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
- TABLE 66. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
- TABLE 67. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
- TABLE 68. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
- TABLE 69. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
- TABLE 70. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
- TABLE 71. VIATRIS INC.: KEY EXECUTIVES
- TABLE 72. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 73. VIATRIS INC.: PRODUCT SEGMENTS
- TABLE 74. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 75. UCB PHARMA: KEY EXECUTIVES
- TABLE 76. UCB PHARMA: COMPANY SNAPSHOT
- TABLE 77. UCB PHARMA: PRODUCT SEGMENTS
- TABLE 78. UCB PHARMA: PRODUCT PORTFOLIO
- TABLE 79. BIOGEN: KEY EXECUTIVES
- TABLE 80. BIOGEN: COMPANY SNAPSHOT
- TABLE 81. BIOGEN: PRODUCT SEGMENTS
- TABLE 82. BIOGEN: PRODUCT PORTFOLIO
- TABLE 83. BIOGEN: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033
- FIGURE 02. SEGMENTATION OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET,2023-2033
- FIGURE 03. TOP IMPACTING FACTORS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2023 TO 2033)
- FIGURE 04. TOP INVESTMENT POCKETS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2024-2033)
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. HIGH INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023 AND 2033(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY COUNTRY 2023 AND 2033(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY 2023 AND 2033(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY COUNTRY 2023 AND 2033(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
- FIGURE 19. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET BY REGION, 2023 AND 2033(%)
- FIGURE 20. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 21. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 22. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 23. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 24. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 25. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 26. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 27. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 29. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 30. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 31. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 32. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 33. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 34. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
- FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2024)
- FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2024)
- FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2024)
- FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 43. COMPETITIVE DASHBOARD
- FIGURE 44. COMPETITIVE HEATMAP: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET
- FIGURE 45. TOP PLAYER POSITIONING, 2023
- FIGURE 46. JOHNSON AND JOHNSON: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 48. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 51. MERCK & CO INC: NET SALES, 2020-2022 ($MILLION)
- FIGURE 52. MERCK & CO INC: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 53. MERCK & CO INC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 59. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 60. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 61. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 63. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 64. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 65. UCB PHARMA: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 66. UCB PHARMA: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 67. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 68. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook